Navigation Links
Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity
Date:12/1/2008

St. Jude study shows the Prox1 gene is a two-way switch that, if turned off, causes lymphatic endothelial cells to be reprogrammed so that they lose their identity and become more like blood endothelial cells

MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNewswire/ --Scientists at St. Jude Children's Research Hospital have discovered that a certain differentiated cell type is so ready to change its identity that it requires the constant expression of a gene called Prox1 to dissuade it.

The researchers showed that Prox1 acts as a two-way switch whose inactivity is sufficient to reprogram a specialized type of cell, called a lymphatic endothelial cell (LEC). In the absence of active Prox1, the LEC actually loses its identity and assumes characteristics of a blood endothelial cell (BEC), which plays a different role in the body. Endothelial cells line the inside of blood and lymphatic vessels. The results of the study appear in the Dec. 1, 2008, issue of the journal Genes & Development.

The new finding is important because it helps to explain how during embryogenesis a critical set of vessels called the lymphatic vasculature arises from veins; and how lymphatic vessels can eventually lose their characteristics and acquire features typical of blood vessels and transport blood -- a trick that might, for example, let the body quickly build up a supply of additional blood vessels when there is an emergency need for more nourishment in a certain area. A switch from lymphatic to blood vessels might also be triggered by certain tumors trying to nourish their own growth.

The lymphatic vasculature is a vital network of vessels that performs important housekeeping functions in the body. Specifically, it drains fluids that normally escape from capillaries, which provide nutrients to the body's cells. The lymphatic vasculature is also part of the immune system that traps and attacks invading organisms and is a primary route for malignant tumor dissemination to the regional lymph nodes.

"The new finding adds to a growing body of evidence showing that some fully differentiated cell types can exhibit great plasticity and upon reprogramming revert back to their previous identity," said Guillermo Oliver, Ph.D., a member of the St. Jude Department of Genetics and Tumor Cell Biology. Differentiation is the process by which genetic activity causes an immature cell type to acquire specific characteristics of a particular mature adult cell type.

"In the last few years, some discoveries have challenged the long-standing belief that cell differentiation is an irreversible final process," said Oliver, the paper's senior author. "St. Jude researchers showed that lymphatic endothelial cells are one of the few examples of differentiated cell types that require constant expression of a specific gene to maintain their identity. This current work builds on our previous results that demonstrated the key role Prox1 plays in the formation of the lymphatic vasculature."

As an important resource for this finding, Oliver's team used a special mouse strain in which the Prox1 genes could be deleted from LECs at different times during development or after birth.

The St. Jude team found that deletion of Prox1 in LECs promoted their reprogramming into BECs as indicated by the expression of specific LEC and BEC proteins. In addition, the newly reprogrammed cells gained some specific features typical of blood vessels. For example, the cells were surrounded by pericytes -- small cells that help support endothelial cells -- and blood abnormally entered the reprogrammed mutant lymphatic vessels.

Finally, the researchers used a trick that enabled them to block the ability of isolated cultured LECs to produce the Prox1 proteins to further demonstrate that Prox1 activity is required by LECs to maintain their identity.

"The new insights offered by this research will give us a better understanding of how to convert one cell into another and the eventual use of the new therapeutic approaches in pathological conditions and tumors," Oliver said.

Other authors of this article include Nicole C. Johnson, Miriam E. Dillard and Sharon L. Frase (St. Jude); Peter Baluk and Donald M. McDonald (University of California, San Francisco); and Natasha L. Harvey (The Hanson Institute, Adelaide, Australia).

This work was supported in part by the National Institutes of Health, a Cancer Center Support Grant and ALSAC.

St. Jude Children's ResearchHospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit www.stjude.org.


'/>"/>
SOURCE St. Jude Children's Research Hospital
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
5. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
6. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
9. RICE MEMORIAL HOSPITAL PHARMACY STAFF EXPERIENCES A 55% REDUCTION IN TIME SPENT MANAGING PATIENT-SPECIFIC MEDICATIONS USING OMNICELL SINGLEPOINTE SOLUTION
10. Novare Announces Completion of First Pediatric Single Port Spleen Removal Using RealHand(R) HD Instruments
11. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that really works. ... be incorporated into the post-surgical treatment plans of a variety of other procedures including, ... is very effective for bruising and causes a rapid resolution of bruising and inflammatory ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Seema Daulat, a native Texan and University ... Lamar location as of July 13, 2016. , Dr. Daulat earned her Doctorate of ... she regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following medical ...
Breaking Medicine News(10 mins):